Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Fierce Pharma
Summit's global PD-1xVEGF data show new promising OS trend
With a fresh data cut in September, the death risk reduction by the ivonescimab regimen expanded to 22% with an improved nominal p value of 0.0332.
Angus Liu
Sep 7, 2025 3:30am
Fierce Pharma
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
AstraZeneca, Daiichi share data behind Dato-DXd do-over
Dec 6, 2024 5:21am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
AstraZeneca plants an EGFR tree with Pinetree deal worth $45M
Jul 23, 2024 2:16pm
Blueprint drops lung cancer programs after seeing early data
Jan 9, 2024 9:22am
